FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss

Audiologists and ENT teams treating patients with the relevant genetic form of hearing loss should become familiar with Otarmeni's approved indication and refer eligible patients to gene therapy specialists; this is a practice-changing regulatory milestone.

This is the first FDA-approved gene therapy for genetic hearing loss, marking a paradigm shift from amplification-based management toward curative intervention for eligible patients.

1. 01FDA approved Regeneron's Otarmeni as the first gene therapy for genetic hearing loss.
2. 02Approval marks a historic shift toward potentially curative treatment rather than amplification alone.
3. 03Targets a specific genetic mutation responsible for congenital or early-onset hearing loss.
4. 04Clinicians will need pathways for genetic screening and specialist referral.
5. 05Long-term safety and efficacy data beyond the approval trial are still being gathered.